A股異動 | 海辰藥業(300584.SZ)午後直線拉昇 對外投資公司獲得藥物臨牀試驗批准
格隆匯11月17日丨海辰藥業(300584.SZ)午後直線拉昇,一度大漲超19%報29.97元,現漲幅收窄至6.6%,報26.8元,暫成交7506萬元,最新總市值32億元。海辰藥業今日午間公佈,公司對外投資的NMS集團下屬子公司Nerviano Medical Sciences S.r.l.於近日收到國家藥監局簽發的《藥物臨牀試驗批准通知書》,藥品為NMS-03305293膠囊,臨牀前研究表明該藥品具備穿透血腦屏障的能力,因此具有治療中樞神經腫瘤和腦轉移腫瘤的潛力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.